Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as AL-3789 Sterile Suspension
AL-3789 Sterile · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| AL-3789 | EXPERIMENTAL | AL-3789 Sterile Suspension, single depot administration of 0.8 mL in the study eye |
| No treatment | NO_INTERVENTION | Fellow eye, as randomized |
| Name | Type | Description |
|---|---|---|
| AL-3789 Sterile Suspension | DRUG | Single administration by anterior juxtascleral depot |
Inclusion Criteria: * Diagnosis of open-angle glaucoma and treated for at least 30 days prior to Screening Visit with a topical prostaglandin analog as monotherapy. * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Pregnant, intend to become pregnant, breastfeeding. * D...
Top 3 of 5 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 3 | PHASE4 | Travoprost Intraocular, high elution |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE4 | Bimatoprost ophthalmic solution |
| AbbVie, Inc. | ABBV | 1 | PHASE4 | bimatoprost |
AL-3789 Sterile is an investigational small molecule developed by Alcon Inc. (ticker ALC) for open-angle glaucoma, an ophthalmology condition. It is a sterile formulation given as a suspension. The drug has been studied in a Phase 2 clinical trial evaluating its ability to lower intraocular pressure over 24 hours.
AL-3789 Sterile is being developed for open-angle glaucoma. The Phase 2 trial of the drug enrolled 25 participants with open-angle glaucoma and measured intraocular pressure lowering efficacy over a 24 hour period. It is an investigational therapy and is not approved for commercial use.
AL-3789 Sterile is developed by Alcon Inc., which trades under the ticker ALC. Alcon is the sponsor of the Phase 2 clinical program evaluating the drug in open-angle glaucoma. The company holds the asset as part of its ophthalmology pipeline.
AL-3789 Sterile is in Phase 2 clinical development. One Phase 2 trial has been completed, and no trials are currently active. The completed study, NCT00643669, evaluated 24 hour intraocular pressure lowering efficacy in 25 participants with open-angle glaucoma in the United States.
AL-3789 Sterile has been studied in one clinical trial, NCT00643669, titled 24 Hour IOP Lowering Efficacy of AL-3789. The Phase 2 trial was completed, enrolled 25 participants, was randomized, and used a no-treatment control. It enrolled adults 18 years and older of all sexes in the United States.
Yes. AL-3789 Sterile Suspension is an alternative name for AL-3789 Sterile, the investigational small molecule developed by Alcon Inc. for open-angle glaucoma. Both names refer to the same Phase 2 asset studied in the completed trial NCT00643669.